USMLE Hematology-Oncology: Multiple Myeloma, CRAB Features, Monoclonal Proteins, Bone Lesions

What This Is and Why It Matters for USMLE

Multiple Myeloma is a high-yield topic for Step 1, Step 2 CK, and Step 3. It is a type of plasma cell malignancy that affects bone marrow and is characterized by the production of monoclonal proteins. This topic is frequently tested on the USMLE, particularly in the context of bone lesions, CRAB features, and monoclonal proteins.

High-Yield Facts (What You Must Memorize)

• Pathophysiology: Multiple myeloma is a cancer of plasma cells in the bone marrow, leading to an overproduction of monoclonal proteins.
• Classic presentation: Bone pain, anemia, hypercalcemia, renal failure, and infections.
• Diagnostic approach:
  • Lab tests: serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and beta-2 microglobulin levels.
  • Imaging: X-rays, CT scans, and MRI to evaluate bone lesions.
• First-line treatment and management:
  • Induction therapy with bortezomib, lenalidomide, or melphalan.
  • Stem cell transplantation.
  • Supportive care: pain management, antibiotics, and hydration.
• Red flags, complications, and follow-up:
  • Hypercalcemia, renal failure, and infections are life-threatening complications.
  • Regular monitoring of serum protein levels, kidney function, and bone density.

Clinical Pearls & Buzzwords

• CRAB features: Hypercalcemia, Renal failure, Anemia, and Bone lesions.
• Monoclonal proteins: Produced by malignant plasma cells, leading to an overproduction of a single type of immunoglobulin.
• Bone lesions: Lytic lesions, osteopenia, and vertebral compression fractures.
• High-risk features: High beta-2 microglobulin levels, high serum protein levels, and poor performance status.

Step-by-Step Clinical Reasoning

1. Identify the syndrome or presentation: Suspect multiple myeloma in patients with bone pain, anemia, and hypercalcemia.
2. Generate a differential: Include other causes of bone pain, such as osteoporosis, metastatic cancer, and Paget's disease.
3. Order appropriate initial tests: Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and beta-2 microglobulin levels.
4. Interpret results: Elevated monoclonal protein levels and beta-2 microglobulin levels support the diagnosis.
5. Initiate treatment and monitoring: Induction therapy, stem cell transplantation, and supportive care.

Missing a life-threatening complication: Failing to recognize and manage hypercalcemia, renal failure, or infections can lead to severe consequences.

Common Mistakes & Exam Traps

• The mistake: Failing to consider multiple myeloma in the differential diagnosis.
• Why it happens: Rushing through the exam or not considering all possible causes of bone pain.
• How to avoid it: Take your time and consider all possible causes of bone pain, including multiple myeloma.

• Exam board insight: The examiners want to test your ability to think critically and consider all possible causes of a patient's symptoms.

• The mistake: Failing to recognize the importance of monoclonal proteins in the diagnosis of multiple myeloma.

• Why it happens: Not understanding the pathophysiology of multiple myeloma.
• How to avoid it: Review the pathophysiology of multiple myeloma and the role of monoclonal proteins in the diagnosis.

• Exam board insight: The examiners want to test your understanding of the pathophysiology of multiple myeloma.

• The mistake: Failing to manage hypercalcemia, renal failure, or infections in patients with multiple myeloma.

• Why it happens: Not understanding the complications of multiple myeloma or not managing them promptly.
• How to avoid it: Review the complications of multiple myeloma and the importance of prompt management.
• Exam board insight: The examiners want to test your ability to manage complications promptly and effectively.

How It’s Tested on USMLE

• Step 1: Basic science vignette, such as a molecular mechanism or pathology slide.
• Step 2 CK: Clinical vignette, such as a patient with bone pain and anemia.
• Step 3: Similar to Step 2 CK, plus prognosis, risk factors, and CCS management.

CCS (Step 3) Relevance (If Applicable)

• Initial orders: Order serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and beta-2 microglobulin levels.
• Monitoring and follow-up: Regularly monitor serum protein levels, kidney function, and bone density.
• Common mistakes: Not ordering indicated tests or delaying treatment can lead to poor outcomes.

Practice Questions (3-5 single-best-answer)

• Question: A 65-year-old man presents with bone pain and anemia. His serum protein electrophoresis (SPEP) shows a monoclonal protein spike. Which of the following is the most likely diagnosis?
  • A) Osteoporosis
  • B) Multiple myeloma
  • C) Metastatic cancer
  • D) Paget's disease
• Answer: B

• Explanation: The patient's symptoms and SPEP results are consistent with multiple myeloma.

• Question: A patient with multiple myeloma is treated with bortezomib. Which of the following is a common side effect of this medication?

  • A) Hypercalcemia
  • B) Renal failure
  • C) Neuropathy
  • D) Infections
• Answer: C

• Explanation: Bortezomib can cause neuropathy as a side effect.

• Question: A patient with multiple myeloma has a serum beta-2 microglobulin level of 5 mg/L. Which of the following is the most likely prognosis?

  • A) Good prognosis
  • B) Poor prognosis
  • C) Intermediate prognosis
  • D) Uncertain prognosis
• Answer: B
• Explanation: A beta-2 microglobulin level of 5 mg/L is associated with a poor prognosis in multiple myeloma.

Quick Reference Card (60-Second Summary)

• CRAB features: Hypercalcemia, Renal failure, Anemia, and Bone lesions.
• Monoclonal proteins: Produced by malignant plasma cells, leading to an overproduction of a single type of immunoglobulin.
• Bone lesions: Lytic lesions, osteopenia, and vertebral compression fractures.
• High-risk features: High beta-2 microglobulin levels, high serum protein levels, and poor performance status.
• First-line treatment: Induction therapy with bortezomib, lenalidomide, or melphalan.

If You Get Stuck on Test Day

• Eliminate obviously wrong answers: Use the process of elimination to narrow down the options.
• Use the "next best step" hierarchy: Consider the least invasive and most specific next step in diagnosis or management.
• For Step 3 CCS: Order basic labs, vitals, and IV access when unsure.

Related USMLE Topics

• Lymphoma: Connects to multiple myeloma through the shared pathophysiology of plasma cell malignancies.
• Bone marrow transplantation: Connects to multiple myeloma through the use of stem cell transplantation as a treatment option.
• Paraproteins: Connects to multiple myeloma through the production of monoclonal proteins.